# Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Source: https://onco.cc/trials/nct07022483/  
OnCo record `nct07022483` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab deruxtecan in endometrial cancer, run by Daiichi Sankyo, now recruiting.

## Summary

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer is a phase 3 interventional study registered as NCT07022483 by Daiichi Sankyo, with 710 participants planned, started 2025-09-30 and due to reach its primary completion in 2032-03-23. Interventions recorded: Trastuzumab Deruxtecan, Chemotherapy. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07022483
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
- Sponsor: Daiichi Sankyo
- Enrolled: 710

## Sources

- ClinicalTrials.gov NCT07022483: https://clinicaltrials.gov/study/NCT07022483

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct07022483.json